GH Research Gains on Potential Acquisition Talks Involving Eli Lilly and Atai Life Sciences

Shares of GH Research rose in premarket trading amid speculation that Eli Lilly is discussing a potential acquisition of Atai Life Sciences. The news boosted investor sentiment across the psychedelic drug sector, with analysts highlighting similarities between GH Research's flagship asset and Atai’s program.

By Fiona Craig Thu, July 16, 2026 at 1:33 PM GMT+3 1 min read · Yahoo Finance · July 16, 2026, 10:33 UTC

Tickers: $ATAI $GHRS $LLY

Topics: acquisition rumors Atai Life Sciences Eli Lilly GH Research psychedelic drug developers

Read the full article at Yahoo Finance

More World news

Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC
Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC
Global Payments Shares Drop 12% Following Reports Private Equity Firms Abandoned Takeover Bid Seeking Alpha · November 12, 2026, 17:14 UTC
Nvidia Appoints Colette Kress as Interim CEO Following Jensen Huang's Resignation CNBC · November 12, 2026, 16:59 UTC
Brookfield Corporation Reports Strong Third Quarter Earnings Growth and Increased Share Buybacks Motley Fool · November 12, 2026, 17:08 UTC
Franco-Nevada Reports Q3 2026 Revenue Growth Driven by Higher Gold and Oil Prices Motley Fool · November 12, 2026, 17:10 UTC
Stratasys Reports Q3 2026 Revenue Growth Driven by Aerospace and Defense Demand Motley Fool · November 12, 2026, 17:11 UTC
Jim Cramer Advises Profit-Taking Following Jensen Huang's Resignation at Nvidia CNBC · November 12, 2026, 16:59 UTC